By combining expression analysis, survival analysis, and wet and dry research validation, a key pathway (hsa-miR-378-5p-APOC1/CEP55) of esophageal squamous cell carcinoma progression after neoadjuvant immunotherapy was identified. The gene discussed is CEP55; the disease is esophageal squamous cell carcinoma.